Oppenheimer raised the firm’s price target on Arvinas (ARVN) to $45 from $40 and keeps an Outperform rating on the shares following quarterly results. The firm continues to believe VERITAC-2 will get vepdeg to market, while the activity in ESR1-mutant vs. wild-type will inform the commercial opportunity. It’s hard to find reasons against optimism at this valuation, Oppenheimer adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas price target lowered to $51 from $63 at Stifel
- Arvinas price target lowered to $81 from $87 at H.C. Wainwright
- Arvinas Holding Company Receives ‘Buy’ Rating: Promising Clinical Advances and Strategic Pipeline Developments
- Arvinas Reports 2024 Financial Results and Pipeline Progress
- Positive Outlook for Arvinas’ Vepdeg and Strategic Expansion Justifies Buy Rating